Zentalis Pharmaceuticals, Inc. - 8-K Filing
Zentalis Pharmaceuticals reported $211.8 million in cash, cash equivalents, and marketable securities as of March 31, 2026, providing a runway into late 2027 to support key clinical milestones for its investigational WEE1 inhibitor azenosertib. The company selected the pivotal dose (400mg QD 5:2) based on favorable data from DENALI Part 2a and expects topline results by year-end 2026, while also initiating ASPENOVA Phase 3 trial in Cyclin E1-positive platinum-resistant ovarian cancer. R&D expenses rose $1.5 million quarter-over-quarter due to clinical advancements. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $ZNTL